FIGHT-207
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
- NCT03822117 ↗
- Terminated
- Incyte Corporation
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on FIGHT-207 (pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on FIGHT-207 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 4 posts on X | |
| 1 YouTube video |
The trial
ClinicalTrials.gov- Official title
- A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
- Phase
- Phase 2
- Status
- Terminated
- Conditions
- Solid Tumor Malignancy
- Interventions
- Pemigatinib
- Arms
- Pemigatinib · Experimental
- Enrollment
- 111
- Primary outcomes
- Objective Response Rate (ORR), Defined as the Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) Based on RECIST v1.1 or RANO, in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements
- ORR, Defined as the Percentage of Participants With a Best Overall Response of CR or PR Based on RECIST v1.1 or RANO, in Participants With Known or Likely Activating FGFR1-3 Mutations
- Sponsor
- Incyte Corporation
- Start
- Oct 17, 2019
- Primary completion
- Mar 29, 2022
- Results posted
- Yes
- Registry record
- NCT03822117 · updated Nov 4, 2025
Publications
linked from the registry- Rodon J, Damian S, Furqan M, Garcia-Donas J, Imai H, Italiano A, Spanggaard I, Ueno M, Yokota T, Veronese ML, Oliveira N, Li X, Gilmartin A, Schaffer M, Goyal L. Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nat Med. 2024 Jun;30(6):1645-1654. doi: 10.1038/s41591-024-02934-7. Epub 2024 May 6. PubMed 38710951